RxDoctor Payments DataLook up a doctor →

Ernesto Alonso, MD

Clinical Neurophysiology · Lake City, FLNPI 1396170601

Payments from drug & device makers

$480,701in general payments, 2019–2025

Across 1,547 payments — averaging $310.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Innovation$271K
  • AbbVie$180K
  • Axsome Therapeutics, Inc.$10K
  • Lundbeck LLC$2K
  • Lilly USA, LLC$1K
  • Novartis$1K
  • plus $15K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ipsen Innovation137$271,417
AbbVie(2 entities)365$179,560
Axsome Therapeutics, Inc.14$9,674
Lundbeck LLC153$2,240
Lilly USA, LLC58$1,124
Novartis63$1,102
Amgen53$1,069
Biogen52$939
Eisai Inc.47$910
Teva Pharmaceuticals USA, Inc.56$836
AstraZeneca(2 entities)35$767
SK Life Science, Inc.37$763
Pfizer32$584
Genentech USA, Inc.23$502
Jazz Pharmaceuticals Inc.21$485
UCB, Inc.24$469
Argenx US, Inc.18$452
Harmony Biosciences LLC23$450
Kyowa Kirin, Inc.23$417
Tanabe Pharma America, Inc.19$386
MDD US Operations, LLC5$386
EMD Serono, Inc.21$381
E.r. Squibb & Sons, L.L.C.3$359
Amneal Pharmaceuticals LLC11$343
Abbott3$333
CSL Behring14$325
Supernus Pharmaceuticals, Inc.18$298
Otsuka America Pharmaceutical, Inc.14$296
Acadia Pharmaceuticals Inc15$289
Corium, LLC13$270
Alnylam Pharmaceuticals Inc.20$262
Bristol Myers Squibb13$242
Adamas Pharmaceuticals, Inc.15$240
Impel Pharmaceuticals Inc.16$231
Neurelis, Inc.10$201
Johnson & Johnson(2 entities)7$166
Sunovion Pharmaceuticals Inc.9$156
Neurocrine Biosciences, Inc.6$153
Greenwich Biosciences, Inc.7$142
Merz Pharmaceuticals, LLC4$109
Octapharma USA, Inc.4$102
TG Therapeutics, Inc.4$102
Upsher-smith Laboratories LLC6$101
Biohaven Pharmaceuticals, Inc.5$87
Grifols USA, LLC4$85
Inspire Medical Systems, Inc.4$85
Sanofi5$81
GRT US Holding, Inc.3$67
Boston Scientific3$66
Biohaven Pharmaceutical Holding Company Ltd.4$63
Averitas Pharma Inc.2$62
Strongbridge US Inc.4$61
Livanova USA, Inc.3$53
Takeda Pharmaceuticals U.S.A., Inc.2$50
Scilex Pharmaceuticals Inc.3$43
Akcea Therapeutics, Inc.2$40
Catalyst Pharmaceuticals, Inc.1$34
Assertio Therapeutics, Inc.2$34
Zyla Life Sciences, Inc.2$32
Acorda Therapeutics, Inc1$23

How this compares

Too few clinical neurophysiology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,086,848
Medicare patients
760
Services billed
61,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other clinical neurophysiology in Lake City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →